Insider Trading Alert - CZNC, SSP And AMRI Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Friday, June 5, 2015, 80 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $368.50 to $15,580,000.00.

Highlighted Stocks Traded by Insiders:

Citizens and Northern (CZNC) - FREE Research Report

Scovill J Bradley, who is President & CEO at Citizens and Northern, bought 5,000 shares at $19.50 on June 5, 2015. Following this transaction, the President & CEO owned 20,174 shares meaning that the stake was boosted by 32.95% with the 5,000-share transaction.

The shares most recently traded at $19.77, up $0.27, or 1.37% since the insider transaction. Historical insider transactions for Citizens and Northern go as follows:

  • 4-Week # shares bought: 46
  • 4-Week # shares sold: 1,500
  • 12-Week # shares bought: 10,349
  • 12-Week # shares sold: 1,500
  • 24-Week # shares bought: 10,934
  • 24-Week # shares sold: 2,150

The average volume for Citizens and Northern has been 21,200 shares per day over the past 30 days. Citizens and Northern has a market cap of $237.6 million and is part of the financial sector and banking industry. Shares are down 5.76% year-to-date as of the close of trading on Friday.

Citizens & Northern Corporation operates as the bank holding company for Citizens & Northern Bank that provides a range of banking and mortgage services to individual and corporate customers in North Central Pennsylvania and Southern New York. The stock currently has a dividend yield of 5.34%. The company has a P/E ratio of 14.4. Currently, there are no analysts who rate Citizens and Northern a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CZNC - FREE

TheStreet Quant Ratings rates Citizens and Northern as a hold. The company's strengths can be seen in multiple areas, such as its expanding profit margins, reasonable valuation levels and increase in stock price during the past year. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, weak operating cash flow and deteriorating net income. Get the full Citizens and Northern Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

E W Scripps (SSP) - FREE Research Report

Wesolowski Timothy M, who is SVP, CFO and Treasurer at E W Scripps, bought 627 shares at $24.98 on June 5, 2015. Following this transaction, the SVP, CFO and Treasurer owned 64,391 shares meaning that the stake was boosted by 0.98% with the 627-share transaction.

Koors Mark L, who is VP/Audit and Compliance at E W Scripps, sold 15,034 shares at $23.65 on June 5, 2015. Following this transaction, the VP/Audit and Compliance owned 34,639 shares meaning that the stake was reduced by 30.27% with the 15,034-share transaction.

The shares most recently traded at $24.18, up $0.53, or 2.17% since the insider transaction. Historical insider transactions for E W Scripps go as follows:

  • 4-Week # shares bought: 257,333
  • 4-Week # shares sold: 657,769
  • 12-Week # shares bought: 257,333
  • 12-Week # shares sold: 657,769
  • 24-Week # shares bought: 257,333
  • 24-Week # shares sold: 915,102

The average volume for E W Scripps has been 490,100 shares per day over the past 30 days. E W Scripps has a market cap of $1.7 billion and is part of the services sector and media industry. Shares are up 7.87% year-to-date as of the close of trading on Friday.

The E. W. Scripps Company, together with its subsidiaries, operates as a media enterprise with interests in television stations, newspapers, and local and national digital media sites. The company has a P/E ratio of 229.9. Currently, there are 3 analysts who rate E W Scripps a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SSP - FREE

TheStreet Quant Ratings rates E W Scripps as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including unimpressive growth in net income, poor profit margins and weak operating cash flow. Get the full E W Scripps Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Albany Molecular Research (AMRI) - FREE Research Report

Hagen Steven R, who is SVP Manufacturing & Pharmaceut at Albany Molecular Research, sold 787 shares at $19.58 on June 5, 2015. Following this transaction, the SVP Manufacturing & Pharmaceut owned 28,700 shares meaning that the stake was reduced by 2.67% with the 787-share transaction.

The shares most recently traded at $20.24, up $0.66, or 3.26% since the insider transaction. Historical insider transactions for Albany Molecular Research go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 41,713
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 85,213
  • 24-Week # shares bought: 30,000
  • 24-Week # shares sold: 207,998

The average volume for Albany Molecular Research has been 454,400 shares per day over the past 30 days. Albany Molecular Research has a market cap of $654.4 million and is part of the health care sector and drugs industry. Shares are up 23.28% year-to-date as of the close of trading on Friday.

Albany Molecular Research, Inc., a contract research and manufacturing company, provides integrated drug discovery, development, and manufacturing services primarily in the United States, Europe, and Asia. Currently, there are 2 analysts who rate Albany Molecular Research a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on AMRI - FREE

TheStreet Quant Ratings rates Albany Molecular Research as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, good cash flow from operations and solid stock price performance. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share. Get the full Albany Molecular Research Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

More from Markets

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Inside Carnival's Mind Blowing New Horizon Cruise Ship (Video)

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Jim Cramer: The 10-Year Yield Could Go to 2.75%

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%